Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer

被引:77
作者
Gulmann, C
Sheehan, KM
Kay, EW
Liotta, LA
Petricoin, EF
机构
[1] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland
[2] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[3] NCI, FDA, Clin Prote Program, Pathol Lab, Bethesda, MD 20892 USA
[4] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA
关键词
proteomics; protein microarrays; biomarker discovery; bioinformatics; cancer;
D O I
10.1002/path.1958
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human proteome, due to the enormity of post-translational permutations that result in large numbers of isoforms, is much more complex than the genome and alterations in cancer can occur in ways that are not predictable by translational analysis alone. Proteomic analysis therefore represents a more direct way of investigating disease at the individual patient level. Furthermore, since most novel therapeutic targets are proteins, proteomic analysis potentially has a central role in patient care. At the same time, it is becoming clear that mapping entire networks rather than individual markers may be necessary for robust diagnostics as well as tailoring of therapy. Consequently, there is a need for high-throughput multiplexed proteomic techniques, with the capability of scanning multiple cases and analysing large numbers of endpoints. New types of protein arrays combined with advanced bioinformatics are currently being used to identify molecular signatures of individual tumours based on protein pathways and signalling cascades. It is envisaged that analysing the cellular 'circuitry' of ongoing molecular networks will become a powerful clinical tool in patient management. Copyright (c) 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:595 / 606
页数:12
相关论文
共 65 条
[1]   Mass spectrometry in proteomics [J].
Aebersold, R ;
Goodlett, DR .
CHEMICAL REVIEWS, 2001, 101 (02) :269-295
[2]   A mathematical model of combination therapy using the EGFR signaling network [J].
Araujo, RP ;
Petricoin, EF ;
Liotta, LA .
BIOSYSTEMS, 2005, 80 (01) :57-69
[3]   Protein microchips: Use for immunoassay and enzymatic reactions [J].
Arenkov, P ;
Kukhtin, A ;
Gemmell, A ;
Voloshchuk, S ;
Chupeeva, V ;
Mirzabekov, A .
ANALYTICAL BIOCHEMISTRY, 2000, 278 (02) :123-131
[4]   High-throughput mapping of a dynamic signaling network in mammalian cells [J].
Barrios-Rodiles, M ;
Brown, KR ;
Ozdamar, B ;
Bose, R ;
Liu, Z ;
Donovan, RS ;
Shinjo, F ;
Liu, YM ;
Dembowy, J ;
Taylor, IW ;
Luga, V ;
Przulj, N ;
Robinson, M ;
Suzuki, H ;
Hayashizaki, Y ;
Jurisica, I ;
Wrana, JL .
SCIENCE, 2005, 307 (5715) :1621-1625
[5]   Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis [J].
Belluco, C ;
Mammano, E ;
Petricoin, E ;
Prevedello, L ;
Calvert, V ;
Liotta, L ;
Nitti, D ;
Lise, M .
CLINICA CHIMICA ACTA, 2005, 357 (02) :180-183
[6]  
Blay Jean-Yves, 2005, Bull Cancer, V92, pE13
[7]   Proteomics in diagnostic pathology - Profiling and imaging proteins directly in tissue sections [J].
Chaurand, P ;
Sanders, ME ;
Jensen, RA ;
Caprioli, RM .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (04) :1057-1068
[8]   Development of a protein microarray using sequence-specific DNA binding domain on DNA chip surface [J].
Choi, YS ;
Pack, SP ;
Yoo, YJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 329 (04) :1315-1319
[9]   Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers [J].
Curran, S ;
Dundas, SR ;
Buxton, J ;
Leeman, MF ;
Ramsay, R ;
Murray, GI .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8229-8234
[10]   Antibody arrays for high-throughput screening of antibody-antigen interactions [J].
de Wildt, RMT ;
Mundy, CR ;
Gorick, BD ;
Tomlinson, IM .
NATURE BIOTECHNOLOGY, 2000, 18 (09) :989-994